Country: Canada
Language: English
Source: Health Canada
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)
PHARMEL INC
N06DA03
RIVASTIGMINE
1.5MG
CAPSULE
RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5MG
ORAL
100/500
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0140521001; AHFS:
CANCELLED PRE MARKET
2017-09-13
PRODUCT MONOGRAPH PR PHL-RIVASTIGMINE Rivastigmine Hydrogen Tartrate Capsules, House Standard 1.5 mg, 3 mg, 4.5 mg and 6 mg of Rivastigmine (as Rivastigmine Hydrogen Tartrate) Cholinestesterase Inhibitor PHARMEL INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 Date of Revision : April 25, 2016 SUBMISSION CONTROL NO: 193498 _ _ _phl-RIVASTIGMINE Product Monograph _ _Page 2 of 53_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ................................................................................................11 DRUG INTERACTIONS ..................................................................................................22 DOSAGE AND ADMINISTRATION ..............................................................................24 OVERDOSAGE ................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ............................................................26 STORAGE AND STABILITY ..........................................................................................29 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................29 PART II: SCIENTIFIC INFORMATION ...............................................................................30 PHARMACEUTICAL INFORMATION ..........................................................................30 CLINICAL TRIALS ............................................................................................. Read the complete document